In the Pharma Report Winter 2019, we take a retrospective view on some of the legal developments during the second half of 2018 in the Norwegian pharmaceutical sector.
The second half of 2018 continued to be as eventful as the first for legal practitioners in the pharmaceutical sector, particularly from a regulatory standpoint. We are therefore pleased to present a retrospective view on some of these legal developments.
In this edition of our biannual report, you can read about part two of AstraZeneca’s challenge of the Norwegian Medicines Agency’s decision to subject its blockbuster inhaler medicine to generic substitution. You can also read about the proposed amendments on the rules on pharmaceutical advertising and the recent development on administrative fines for breaches of pharmaceutical law.
From an IP-perspective, this edition of Pharma Report provides an overview of the case between Teva / Actavis and Novartis on the validity of the Exforge-patent.
Haavind’s Health and Life Science team continuously and closely monitors developments in Norway relevant to the pharma sector. If you wish to discuss how your business can best meet the legal challenges of this innovative and highly regulated sector, you are always welcome to contact us.